ATE411013T1 - Verfahren zur hemmung der verschlechterung der kognitiven leistungsfähigkeit bei erwachsenen mit down-syndrom - Google Patents

Verfahren zur hemmung der verschlechterung der kognitiven leistungsfähigkeit bei erwachsenen mit down-syndrom

Info

Publication number
ATE411013T1
ATE411013T1 AT02770441T AT02770441T ATE411013T1 AT E411013 T1 ATE411013 T1 AT E411013T1 AT 02770441 T AT02770441 T AT 02770441T AT 02770441 T AT02770441 T AT 02770441T AT E411013 T1 ATE411013 T1 AT E411013T1
Authority
AT
Austria
Prior art keywords
adults
receptor antagonist
glucocorticoid receptor
down syndrome
cognitive performance
Prior art date
Application number
AT02770441T
Other languages
English (en)
Inventor
Joseph Belanoff
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Application granted granted Critical
Publication of ATE411013T1 publication Critical patent/ATE411013T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Toilet Supplies (AREA)
  • Bidet-Like Cleaning Device And Other Flush Toilet Accessories (AREA)
  • Casting Support Devices, Ladles, And Melt Control Thereby (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
AT02770441T 2001-08-31 2002-08-27 Verfahren zur hemmung der verschlechterung der kognitiven leistungsfähigkeit bei erwachsenen mit down-syndrom ATE411013T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31665301P 2001-08-31 2001-08-31

Publications (1)

Publication Number Publication Date
ATE411013T1 true ATE411013T1 (de) 2008-10-15

Family

ID=23230024

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02770441T ATE411013T1 (de) 2001-08-31 2002-08-27 Verfahren zur hemmung der verschlechterung der kognitiven leistungsfähigkeit bei erwachsenen mit down-syndrom

Country Status (15)

Country Link
US (1) US7402578B2 (de)
EP (1) EP1432379B1 (de)
JP (2) JP2005501882A (de)
KR (1) KR20040029116A (de)
CN (2) CN1868480A (de)
AT (1) ATE411013T1 (de)
CA (1) CA2459033C (de)
DE (1) DE60229411D1 (de)
ES (1) ES2314103T3 (de)
IL (1) IL160649A0 (de)
MX (1) MXPA04001893A (de)
NO (1) NO332723B1 (de)
NZ (1) NZ531477A (de)
WO (1) WO2003020216A1 (de)
ZA (1) ZA200401754B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050038580A (ko) * 2001-10-26 2005-04-27 악조 노벨 엔.브이. 주요 우울 장애의 치료에 사용되는(11β,17β)-11-(1,3-벤조디옥솔-5-일)-17-히드록시-17-(1-프로피닐)-에스트라-4,9-디엔-3-온의 용도
HRP20110702T1 (hr) 2007-02-02 2011-10-31 Pfizer Products Inc. Triciklički spojevi i njihova uporaba kao modulatora glukokortikoidnih receptora
AU2009267016B2 (en) * 2008-07-01 2014-07-03 Corcept Therapeutics, Inc. Use of mifepristone for the treatment of Amyotrophic Lateral Sclerosis
EP2576582B1 (de) * 2010-05-26 2019-09-18 Corcept Therapeutics, Inc. Behandlung von muskeldystrophie
US10500216B2 (en) 2011-11-18 2019-12-10 Corcept Therapeutics, Inc. Optimizing mifepristone absorption
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US12226412B2 (en) 2012-05-25 2025-02-18 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US9457141B2 (en) 2013-06-03 2016-10-04 Bigfoot Biomedical, Inc. Infusion pump system and method
US9943526B2 (en) 2015-04-21 2018-04-17 Corcept Therapeutics, Inc. Optimizing mifepristone levels for cushing's patients
FI3897589T3 (fi) 2018-12-19 2026-01-13 Corcept Therapeutics Inc Farmaseuttisia formulaatioita, jotka sisältävät relakorilanttia, heteroaryyliketonifusoitua atsekaliiniyhdistettä
US11285145B2 (en) 2020-05-27 2022-03-29 Corcept Therapeutics Incorporated Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4
WO2022134033A1 (en) 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
IL319657A (en) 2022-10-06 2025-05-01 Corcept Therapeutics Inc Glucocorticoid receptor modulator formulations
WO2024092195A1 (en) 2022-10-28 2024-05-02 Corcept Therapeutics Incorporated Treatments for amyotrophic lateral sclerosis using dazucorilant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001512422A (ja) * 1997-02-05 2001-08-21 アレリツクス・フアーム−エコ・エル・ピー 記憶増強のための薬剤
ATE332696T1 (de) * 1997-10-06 2006-08-15 Univ Leland Stanford Junior Methode zur behandlung von durch glycocorticoidstörungen verursachten psychosen
KR20010043630A (ko) * 1998-05-15 2001-05-25 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 치매의 치료를 위한 글루코코티코이드 수용체 길항제
US6620802B1 (en) * 1999-11-23 2003-09-16 Corcept Therapeutics, Inc. Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist
US20020065259A1 (en) * 2000-08-30 2002-05-30 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
AU2002319665B2 (en) * 2001-07-23 2006-09-21 Corcept Therapeutics, Inc. Methods for preventing antipsychotic-induced weight gain

Also Published As

Publication number Publication date
EP1432379B1 (de) 2008-10-15
ES2314103T3 (es) 2009-03-16
EP1432379A4 (de) 2005-07-13
CA2459033C (en) 2012-05-22
NO20041338L (no) 2004-05-28
US7402578B2 (en) 2008-07-22
ZA200401754B (en) 2005-05-25
KR20040029116A (ko) 2004-04-03
WO2003020216A1 (en) 2003-03-13
MXPA04001893A (es) 2005-03-07
CN1868480A (zh) 2006-11-29
EP1432379A1 (de) 2004-06-30
NO20041338D0 (no) 2004-03-31
JP2009102343A (ja) 2009-05-14
DE60229411D1 (de) 2008-11-27
CN1556708A (zh) 2004-12-22
JP2005501882A (ja) 2005-01-20
CA2459033A1 (en) 2003-03-13
HK1062533A1 (en) 2004-11-12
IL160649A0 (en) 2004-07-25
NZ531477A (en) 2006-10-27
US20030064974A1 (en) 2003-04-03
NO332723B1 (no) 2012-12-27

Similar Documents

Publication Publication Date Title
ATE406166T1 (de) Verfahren zur prävention von gewichtszunahme infolge von antipsychotika
ATE411013T1 (de) Verfahren zur hemmung der verschlechterung der kognitiven leistungsfähigkeit bei erwachsenen mit down-syndrom
ATE317699T1 (de) Glucocorticoid receptor antagonisten zur behandlung von demenz
WO2002076390A3 (en) Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
NO20003534L (no) Progesteronreseptor-modulatorforbindelser, farmasøytiske sammensetninger inneholdende disse og anvendelsen av forbindelsene
DE69835225D1 (de) Methode zur behandlung von durch glycocorticoidstörungen verursachten psychosen
ATE498395T1 (de) Allgemein lineare brauseform von fentanyl zur oralen anwendung und verfahren zur verabreichung
DK1117403T3 (da) MGLUR5-antagonister til behandling af smerte og angst
DE60126537D1 (de) Flüssigkristallprojektor und Verfahren zu dessen Einstellung
HK1047050A1 (zh) 治疗轻度智力机能缺陷的方法
NO20026103D0 (no) 1-amino-alkylcycloheksaner som 5-HT3 og neuronal nikotinreseptorantagonister
WO2004069202A3 (en) Antiglucocorticoids for the treatment of postpartum psychosis
EP0928419A4 (de) Zusammensetzungen und verfahren zur regulierung der expression des type-i-interleukin-1-rezeptors
DE60238671D1 (de) Verwendung von glucocorticoid-rezeptor-spezifischen antagonisten zur behandlung von delirium
NO20042500L (no) Chemokin-reseptorantagonister og metoder for anvendelse derav
IS8388A (is) Blandan af serótónín endurupptökuhindra og histamín 3 viðtaka mótlyfi, öflugum verka eða hlutaverka
WO2002020526A3 (en) Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binding agents
TR199800488T1 (xx) Diskinezi i�in 5-HT3 resept�r antagonistleri.
SE0402459D0 (sv) New hydroxymethylbenzothiazoles amides

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties